Tag:
cabazitaxel
Latest Headlines
Latest Headlines
Sanofi touts reduced death risk in PhIII prostate cancer trial
Sanofi-Aventis touted a 28 percent reduced risk of death and a substantial increase in median overall survival rates among patients taking its prostate cancer drug cabazitaxel in combination with
Sanofi offers promising survival data on prostate cancer drug
Sanofi-Aventis has pulled the curtain back on a slate of promising, late-stage data for its prostate cancer drug cabazitaxel, demonstrating that the therapy prolongs the life of men with advanced
